Adverum Halts Phase II Gene Therapy Trial After Patient’s Vision Loss

 
• By Joseph Haas
  
Adverum's significant adverse event is the latest setback in gene therapy development
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D